Last edition
News about "Oral Solid Dosage "
HAB Pharmaceuticals Charts Growth Path, Targets INR 2,500 to 3,000 Crore Revenue by 2030
HAB Pharmaceuticals is expanding its manufacturing and R&D capabilities while strengthening its specialty product portfolio and global regulatory footprint as it targets revenues of INR 2,500–3,000 crore by 2030.
Oral Solid Dosage | 29/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members